Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
PTC Therapeutics Inc. is currently navigating 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct art units, indicating a highly diversified technical presence within the pharmaceutical sector. The involvement of 3 distinct examiners means that each pending action is being reviewed by a different individual, requiring a tailored response strategy for each case.
MOORE, SUSANNA is the busiest examiner for the portfolio, though she is only responsible for 1 pending office action. This indicates an even distribution where each of the distinct examiners handles exactly one of the pending office actions. Such a distribution prevents any single examiner from having a disproportionate impact on the overall portfolio progress.
With 3 pending office actions across distinct art units, the company's prosecution is decentralized across multiple specialized examination groups. This structure suggests that the Biotechnology & Pharmaceuticals filings cover a wide range of technical sub-fields. Practitioners should prepare for diverse examiner perspectives while managing the 1 pending office action with the busiest examiner. Coordinating across these separate units will be essential for maintaining consistency in the company's pharmaceutical patent strategy.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, SUSANNA | 1 | 68.1% | +31.6% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293122 | METHODS FOR SYNTHESIS OF RACEMIC, SCALEMIC, AND CHIRAL ALPHA-TOCOTRIENOL QUINONE | MOORE, SUSANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17783941 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | ANDERSON, REBECCA L | 14d |
| 18264183 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | MOU, LIYUAN | 29d |
| 18293122 | METHODS FOR SYNTHESIS OF RACEMIC, SCALEMIC, AND CHIRAL ALPHA-TOCOTRIENOL QUINONE | MOORE, SUSANNA | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1628 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18293122 | METHODS FOR SYNTHESIS OF RACEMIC, SCALEMIC, AND CHIRAL ALPHA-TOCOTRIENOL QUINONE | MOORE, SUSANNA | 1624 | §102§103§112 | Final Rejection | — | Pending | Jan 29, 2024 |
| 18264183 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | MOU, LIYUAN | 1628 | §103§112DP | Final Rejection | 29d | Pending | Aug 03, 2023 |
| 17783941 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | ANDERSON, REBECCA L | 1626 | §103DPOther | Final Rejection | 14d | Pending | Jun 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial